Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The collaboration positions Merck KGaA as a credible immuno-oncology platform player despite trailing BMS, Merck & Co., and Roche on PD-1/PD-L1 monotherapy…
The deal expands the platform race in checkpoint immunotherapy, with Ablynx's bi- and tri-specific Nanobody constructs offering a structural alternative to…
The 2015 expansion adding 12 programs and €4B in biobucks underscored Merck's confidence in the original 2014 Nanobody candidates, with Jefferies' Peter…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck KGaA paid Ablynx EUR 20M upfront plus up to EUR 10.7M in research funding and up to EUR 1.7B in development, regulatory and commercial milestones across five Nanobody programs targeting immune checkpoint modulators. The deal vaulted Merck KGaA into the immuno-oncology platform race and was later expanded by an additional EUR 4B in 2015.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Ablynx NV (this deal) | 2014 | $2.3B | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2014 deals · Merck & Co. Inc. deals · Oncology deals